We conducted searches of electronic databases and manual bibliographies. We performed a meta-analysis of all RCTs comparing
tacrolimus with
cyclosporine as primary immunosuppression for lung transplant recipients. Extracted, pooled data for mortality, acute rejection, withdrawals, and adverse events were analyzed using Mantel-Haenszel tests with a random effects model.
RESULTS: Three RCTs including 297 patients were assessed in this study. Mortality at 1 year or more was comparable between lung recipients treated with
tacrolimus and
cyclosporine (odds ratio [OR], 0.94; 95% confidence interval [CI], 0.42-2.10; P = .88).
Tacrolimus-treated patients experienced fewer incidences of acute rejection (MD = -0.14; 95% CI, -0.28 to -0.01; P = .04). Pooled analysis showed a trend toward a lower risk of
bronchiolitis obliterans syndrome (BOS) among
tacrolimus-treated patients, although it did not reach significances (OR, 0.53; 95% CI, 0.25-1.12; P = .10). Fewer patients stopped
tacrolimus than
cyclosporine (OR, 0.12; 95% CI, 0.03-0.48; P = .003). The rate of new-onset diabetes was higher among the
tacrolimus group (OR, 3.69; 95% CI, 1.17-11.62; P = .03). The incidence of
hypertension and renal dysfunction were comparable in these 2 groups (OR, 0.24; 95% CI, 0.03-1.70; P = .15; and OR, 1.67; 95% CI, 0.70-3.96; P = .25, respectively). There was a trend toward lower risk of
malignancy in
tacrolimus-treated patients, although it did not reach significance either (OR, 0.19; 95% CI, 0.03-1.13; P = .07). The incidence of
infection was comparable in these 2 groups (MD = -0.29, 95% CI, -0.68 to 0.11; P = .16).
CONCLUSION: